20 articles
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
New research reveals how fatty liver disease reshapes the tumor microenvironment, potentially accelerating cancer metastasis.
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
Researchers explore targeted immune strategies to improve pancreatic islet transplant success rates for diabetes treatment.
A comprehensive 2025 review maps the metabolic chaos driving diabetic foot ulcers and evaluates emerging treatments from exosomes to gene therapy.
Super-resolution microscopy reveals how mitochondrial mRNAs are distributed, folded, and released during apoptosis inside living cells.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
Researchers shift from systemic B-cell targeting to localized immune control, potentially improving transplant success rates.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
New research reveals pulsed electromagnetic field therapy selectively enhances ATP-linked mitochondrial respiration, pointing to a specific cellular energy mechanism.
Blocking mTOR forces cancer cells to rewire cholesterol uptake and transport, revealing new drug targets when combined with rapamycin.
A novel conjugate merges GLP-1/GIP incretin signaling with pan-PPAR activation in one molecule, potentially revolutionizing metabolic therapy.
Scientists identify how different immune cells use specific nutrient transporters, revealing new targets for autoimmune diseases.
New research reveals semaglutide's liver benefits work independently of weight loss through specialized liver blood vessel cells.
Researchers found a dual-target approach that selectively destroys the most treatment-resistant form of acute myeloid leukemia.
A completed OSU trial investigates whether short-term exercise training can restore impaired mitochondrial cleanup pathways in overweight and obese skeletal muscle.
